MRI in active surveillance: a critical review by Stavrinides, V et al.
 1 
MRI in active surveillance: a critical review 
Vasilis Stavrinides1, Francesco Giganti1,2, Mark Emberton1,3, Caroline M Moore1,3. 
 
Affiliation addresses: 
1 Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley 
Street, W1W 7TS, London, UK 
2 Department of Radiology, University College London Hospitals NHS Trust, 235 Euston Road, NW1 2BU, 
London, UK 



















Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley 





Introduction: Recent technological advancements and the introduction of modern 
anatomical and functional sequences have led to a growing role for multiparametric 
magnetic resonance imaging (mpMRI) in the detection, risk assessment and monitoring of 
early prostate cancer. This includes men who have been diagnosed with lower risk prostate 
cancer and are looking at the option of active surveillance (AS). The purpose of this paper 
is to review the recent evidence supporting the use of mpMRI at different time points in AS, 
as well as to discuss some of its potential pitfalls. 
Methods: A combination of electronic and manual searching methods were used to identify 
recent, important papers investigating the role of mpMRI in AS. 
Results: The high negative predictive value of mpMRI can be exploited for the selection of 
AS candidates. In addition, mpMRI can be efficiently used to detect higher risk disease in 
patients already on surveillance.  
Conclusion: Although there is an ongoing debate regarding the precise nature of its 
optimal implementation, mpMRI is a promising risk stratification tool and should be 





Active surveillance (AS) for early prostate cancer is an alternative to radical surgery or 
radiotherapy that emerged after the growing awareness that many cancers diagnosed 
through prostate-specific antigen (PSA) screening are low-risk and unlikely to 
metastasize(1–3). AS is directed towards men with low or intermediate risk disease with a 
life expectancy of over 10 years and requires that both clinician and patient assess and 
balance the risk of the proven cancer against the potential side effects of radical treatments. 
There currently are many AS programs across the world with excellent outcomes in terms 
of overall and prostate cancer specific mortality(4–8). Although their exact selection criteria 
differ, they all use variations of the D’Amico or National Comprehensive Cancer Network 
(NCCN) classifications to identify low-risk disease (low-risk: PSA ≤10 ng/mL, Gleason score 
≤6, stage T1-T2a; intermediate risk: 10<PSA<20 ng/mL, Gleason score 7, stage T2b; high-
risk: PSA >20  ng/mL, Gleason score ≥8, stage T2c-T3a)(9,10). Patients undergo regular 
clinical examinations, PSA testing and prostate biopsy, while progression is defined using 
pre-established clinical or pathological thresholds for clinical significance. In the AS context 
only “clinically significant” cancers are treated and “progression” implies to a shift from 
“insignificant” to “significant” disease with potential for adverse consequences if the cancer 
remained untreated. 
Multiparametric magnetic resonance imaging (mpMRI) has shown considerable 
potential as a risk stratification tool and is likely to be incorporated more widely into patient 
pathways in coming years(11). The use of imaging parameters to include or exclude men, 
or to routinely reassess men on active surveillance varies between different programmes, 
with a lack of published data on the precise timing of imaging, or of thresholds which should 
prompt additional biopsy or a move to active treatment. The UK National Institute for Health 
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& Care Excellence is the first national body to recommend that MRI is used in men 
considering active surveillance, and that it can also be used instead of, or in addition to 
biopsy during follow up(12).  
 
Multiparametric MRI (mpMRI) 
 
MpMRI consists of a combination of T2-weighted (T2W), diffusion-weighted (DW) and 
dynamic contrast-enhanced (DCE) sequences. There are a number of studies attempting to 
measure the ability of mpMRI to diagnose significant cancer against a reference standard, 
usually either a needle biopsy interrogation of the prostate or pathological specimens 
obtained after radical prostatectomy (RP). On the whole, such studies have demonstrated 
that mpMRI (i) has a high sensitivity and negative predictive value(13,14) (ii) misses mostly 
small, low-grade tumours(15,16) (iii) is associated with clinically significant disease when 
positive(17) and (iv) allows estimation of disease burden at diagnosis. The recently 
published PRECISION study has shown within a randomised controlled trial design that 
when an mpMRI-targeted and standard biopsy approach are compared, there is greater 
detection of clinically significant disease, less detection of clinically insignificant disease and 
fewer men undergo biopsy(18). These attributes are also appealing in the setting of active 
surveillance where it is known that a man has lower risk disease and the aim is to detect 
only that cancer which is more likely to benefit from treatment.  
MpMRI reporting systems standardize the diagnostic process so that results are easier 
to analyze, reproduce and communicate. The Likert scale is a 5-point ordinal scale used to 
assign a likelihood of clinically significant cancer based on mpMRI appearances of the 
lesion and the background of the whole prostate and higher Likert scores (i.e. 4 or 5) are 
associated with increased significant cancer detection(19). Although this scoring system 
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has been applied in important studies such as the PROMIS trial(13), it implies a subjective 
assessment of the whole prostate gland (for example ruling in or out lesions when there is a 
background of inflammation) and is highly influenced by the expertise of the reporting 
radiologist. A more standardised 5-point scoring system (Prostate Imaging Reporting and 
Data System [PI-RADS]) for prostate lesions was introduced in 2012(20) and then updated 
to version 2.0 in 2014(21). In summary, according to this system, the dominant sequence 
for detecting cancer in the peripheral zone is DWI, whereas for the transition zone this is 
T2WI. For DWI, apparent diffusion coefficients (ADC) and high b-values (>1400 s/mm²) are 
mandatory, whereas DCE has a secondary role (only the presence or absence of focal 
enhancement is evaluated). Up to four lesions of category 3, 4 and 5 are allocated on a 
sector map and the index lesion is also identified. 
 
MRI for the selection of AS candidates 
 
Evidence from mpMRI prior to additional biopsy studies in men on AS 
 
 
Studies indicate that mpMRI can be very useful for selecting AS candidates(22–
31)(Table 1). Early work on 85 men fulfilling the Johns Hopkins criteria for AS on standard 
transrectal biopsy (PSA density ≤0.15 ng/mL/cc, ≤2 positive cores, ≤50% tumour in any 
core, Gleason score ≤6, and stage T1c) who had an additional mpMRI and 12-zone-plus-
targeted TRUS biopsy concluded that 29% of patients did not meet AS eligibility criteria(32). 
MpMRI lesion number and degree of suspicion were associated with pathological 
reclassification. Similar work has demonstrated that, in men previously diagnosed using a 
standard systematic approach, mpMRI-plus-targeted biopsy often reclassifies patients as 
AS-ineligible, with reclassification rates ranging from 10% to as high as 59%(22,23). High-
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suspicion lesions on mpMRI (e.g. PIRADS v2 4-5) are strongly associated with underlying 
clinically significant disease and higher reclassification rates(26,28,29). In contrast, 
evidence suggests that low mpMRI suspicion scores are not associated with pathological 
upgrading(30). It has also been shown that clinical decision tools incorporating mpMRI 
scores can predict disqualification from AS and could, therefore, have utility when 
counseling men considering AS(27). Abdi and colleagues assessed whether mpMRI 
combined with mpMRI fusion technology during TRUS biopsy can enhance the detection of 
significant disease in 111 men on AS, using termination of surveillance as the primary end 
point(24). MpMRI increased the rate of AS termination where PI-RADS score of 4 or 5 
(versus 3) was the only significant predictor, essentially meaning that patients with a 
suspicious lesion on mpMRI are more likely to require active treatment. 
Guo and colleagues synthesized findings on mpMRI performance for predicting 
upgrading on confirmatory biopsy by conducting a meta-analysis on diagnostic data from 
1028 patients(33). The pooled sensitivity, specificity, positive likelihood ratio and negative 
likelihood ratio estimates for re-classification were 0.69, 0.78, 3.1 and 0.4, respectively. This 
further reinforces the view that although a negative MRI in an AS candidate is reassuring, 
an MRI lesion should be targeted at biopsy due to the higher risk of harbouring clinically 
significant disease.  
 
Evidence from radical prostatectomy studies in men potentially suitable for AS  
 
Despite some early reports that mpMRI cannot predict upgrading, upstaging or 
positive surgical margins at RP in otherwise AS-eligible men(34), there is a good body of 
evidence suggesting the contrary(35–37) (Table 1). De Cobelli and colleagues reviewed 
2200 men who had a previous RP and isolated 223 patients that fulfilled the Prostate 
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Cancer Research International Active Surveillance (PRIAS) criteria for surveillance (PSA 
level <10 ng/mL at diagnosis, PSA density <0.2 ng/mL/cc, clinical stage T1c or T2, Gleason 
score ≤ 3+3, and one or two biopsy-positive cores)(35). These men had 1.5T mpMRI 6-8 
weeks after TRUS biopsy. Out of 113 patients who experienced upgrading, 112 had MRI-
visible cancer and only one did not and the estimated sensitivity of mpMRI for extracapsular 
extension was 100%.    
Tay and colleagues retrospectively assessed 208 men who underwent RP after 
mpMRI and classified them for AS suitability according to three different AS criteria, i.e. 
Epstein (T1c, PSA ≤10 ng/mL, Gleason ≤6, PSAD ≤ 0.15 ng/mL/cc, ≤ 2 positive cores and 
core involvement ≤50%) and low-risk or extended NCCN criteria (low-risk: Gleason 
≤3+3/PGG 2, Stage ≤T2a, PSA ≤10 ng/mL; extended: Gleason ≤3+4/PGG 1, Stage ≤T2b, 
PSA ≤15 ng/mL)(37). Combining mpMRI with NCCN low-risk clinical criteria resulted in a 
statistically significant improvement in specificity (0.8, 95% CI: 0.28-0.99) and area under 
the curve (0.9, 95% CI: 0.70-1.00) for selecting AS candidates. A retrospective study of 126 
patients who were eligible for AS but treated with RP by Porpiglia and colleagues revealed 
that incorporating mpMRI to multivariate models including the PRIAS (T1c or T2, Gleason 
≤6, ≤2 positive cores, PSA ≤10 ng/mL, PSA density ≤0.2 ng/mL/cc) and Epstein AS criteria 
increased their accuracy for predicting pathologically confirmed insignificant prostate cancer 
by 5% and 7%, respectively(36). In the same study, the sensitivity of mpMRI for detecting 
significant cancer was 73.7%, specificity 60.8%, PPV 60.8% and NPV 73.7%, in line with 
other similar studies (Figure 1). 
 
Repeat mpMRI as a tool to detect change in men on surveillance 
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MpMRI is also of interest in detecting change in men on AS and helping patients with 
stable imaging findings to avoid routine re-biopsy. The optimal imaging schedule to balance 
the costs and benefits of this approach is not well defined, and is likely to differ with 
baseline risk, such that men with either Gleason 3 + 4 disease or a visible lesion are more 
likely to show radiological change over time.  
In an attempt to define the natural history of small mpMRI lesions, Rais-Bahrami and 
colleagues retrospectively reviewed 153 patients who underwent a minimum of two 
mpMRIs followed by mpMRI-TRUS fusion biopsy(38). The growth rate of the lesions was 
calculated from serial scans, using two index lesion size thresholds (5 and 7 mm). The 
lesions were mostly benign (with only up to 13.8% harboring low-grade Gleason 6 cancer) 
and did not change significantly in size over approximately 2 years (2.31±1.56 years and 
2.40±1.77 years for ≤7 mm and ≤5 mm index lesion thresholds, respectively). From these 
findings the authors proposed a monitoring interval of at least two years for small lesions. 
Studies of men already on AS who have had repeat mpMRIs and biopsies are more 
informative(39–45)(Table 2). In a retrospective study, Walton-Diaz and colleagues 
evaluated patients meeting surveillance criteria based on systematic TRUS biopsy, who 
subsequently underwent further systematic biopsies, mpMRI and TRUS targeted biopsies 
during AS until Gleason grade progression occurred and treatment was recommended(39). 
The sensitivity, specificity, negative and positive predictive values were 0.53 (95% CI: 0.28–
0.77), 0.80 (95% CI: 0.65–0.91), 0.80 (95% CI: 0.65–0.91), 0.53 (95% CI: 0.28–0.77), 
respectively. The authors also concluded that the use of mpMRI decreases the number 
needed to biopsy in order to detect one pathological progression from 8.75 to 2.89, thus 
reducing the biopsy-related morbidity burden on the surveillance population. In another 
report from the same study group at the Royal Marsden, UK, reduction in apparent diffusion 
coefficient (ADC) on DWI was associated with pathological progression(46). Specifically, a 
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10% reduction in tumour ADC indicated progression with sensitivity and specificity of 93% 
and 40%, respectively. 
In an interesting study by Felker and colleagues, 49 consecutive men on AS with 
Gleason 6 cancer underwent mpMRI at baseline and at least six months later, each 
followed by a targeted prostate biopsy(40). The authors evaluated whether radiological 
progression (defined as an increase in lesion suspicion score, size or ADC) predicted 
pathological progression (Gleason 3+4 or higher on subsequent biopsy). The addition of 
mpMRI-based parameters to models based on clinical variables increased their predictive 
ability (AUC 0.91 versus 0.87). Additional evidence suggests that high mpMRI suspicion 
scores are directly associated with upgrading, protocol-based treatment change or both(41–
43).  
The question is often asked whether men with a negative mpMRI still need to undergo 
routine biopsies on surveillance and some authors suggest that this is the case. Hamoen 
and colleagues found that, in a subset of 111 men on AS who underwent serial mpMRIs 
and MRI-guided biopsies, systematic TRUS biopsy identified a considerable proportion of 
patients who had a Gleason upgrade to 3+4 (from 3+3) at one year(44). Thurtle and 
colleagues assessed men at baseline and follow up with MRI and biopsy, and concluded 
that at their centre, follow up protocol biopsies identified additional men with Gleason Group 
2 or T3 disease compared to mpMRI and targeted biopsy alone(45). However, they only 
used 2 cores per target, which may have reduced the reliability of the mpMRI-targeted 
approach. Sanguedolce and colleagues have assessed the features on baseline mpMRI 
which predict future progression and concluded that both higher lesion volume and higher 
score are correlated with AS withdrawal and shorter failure-free survival(47).  
Detecting disease progression on mpMRI in imaging-based AS cohorts is limited due 
to a lack of robust data on the natural variability in the appearance of MRI lesions on serial 
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mpMRI(48). The PRECISE recommendations were developed by a European School of 
Oncology task force in order to standardize mpMRI reporting for men who are on AS and 
undergo regular follow up scans(49). A set of important recommendations for mpMRI 
reporting was derived through discussion and scores of consensus among experts from a 
set of 394 statements. As a result, a PRECISE case report form including all important 
radiological characteristics (e.g. lesion size, assessment of likelihood of clinically significant 
disease, likelihood of change from previous scan, parameters that changed etc.) was 
developed in order to facilitate the standardized collection of clinical and imaging data in 
these cohorts. In addition, a PRECISE checklist for reporting imaging-based AS outcomes 
includes key information that investigators need to disclose such as imaging, biopsy and 
clinical attributes. It was not clear to the PRECISE panel which determinant of size was 
most important, although a recent publication looking at 30 men with an index lesion on 
MRI suggests that maximum tumour diameter may be associated with the least inter-
observer reliability(50).  
 
Limitations of mpMRI in active surveillance  
 
Even though mpMRI is a promising tool, there are limitations that should be 
considered and not all studies have demonstrated a clear diagnostic superiority of mpMRI 
compared to existing pathways. Possible reasons are: 
(i) False positives. When selecting AS candidates, mpMRI has a relatively low 
specificity, with false positive results particularly associated with PI-RADS 3 and 
4(51). Non-malignant processes such as adenosis, high-grade prostatic 
intraepithelial neoplasia and post-atrophic hyperplasia within the prostate can mimic 
well-differentiated cancer(52). In addition, technical pitfalls (such as improperly 
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positioned endorectal coils or patient movement), iatrogenic causes (e.g. post biopsy 
changes or granulomatous prostatitis post intravesical BCG instillation) and unusual 
appearance of otherwise normal anatomic structures (e.g. hypertrophic anterior 
fibromuscular stroma) can lead to a similar result(53). False positive findings lead to 
interpretation errors and unnecessary biopsies but, nonetheless, care must be taken 
when the targeted biopsy of a positive mpMRI lesion is negative, as guided biopsies 
of mpMRI lesions (especially TRUS) can be challenging and should be interpreted in 
context(54). 
(ii) False negatives. Although mpMRI sensitivity increases with tumour size and grade, 
retrospective studies correlating images with RP specimens suggest that a small 
proportion of clinically important cancers can be missed or their size underestimated, 
depending on the quality of the scan and its interpretation(55). It is estimated that the 
NPV of mpMRI varies considerably from 0.65 to 0.94 and, therefore, a negative 
mpMRI should be always interpreted in the context of the performance of MRI at that 
centre(56). 
(iii) Variability in infrastructure, image acquisition and interpretation. There appears 
to be some evidence that PI-RADS/Likert score and the assigned probability of 
significant cancer vary considerably among radiologists(57,58). Therefore, there is a 
need for greater clarity of cut-off values for clinically significant disease in different 
clinical settings(59). Use of the PRECISE guidelines to defining reporting criteria for 
baseline and subsequent mpMRI will help with the creation of a robustly reported 







Cost and quality of life considerations 
 
Many urologists believe that mpMRI could be a useful tool for assessing risk in 
biopsy-naïve patients and monitoring AS cohorts, but cost and lack of appropriate 
infrastructure are considered significant obstacles preventing the implementation of 
imaging-based patient pathways(60). Cost-effectiveness analysis suggests that an MRI-
guided prostate cancer diagnostic pathway would result in fewer men needing biopsies and 
greater detection of clinically significant disease, in the prostate cancer detection 
setting(61). However, uncertainty exists regarding the cost effectiveness of mpMRI 
specifically in the AS setting, primarily due to the lack of long-term AS data. An Australian 
study using Markov models and comprehensive sensitivity analyses concluded that the 
mpMRI-plus-targeted biopsy approach in AS produces fewer biopsies, identifies more 
significant cancers and diagnoses less insignificant disease, provided that the uptake of AS 
is increased(62). In the extreme scenario where this strategy was applied to all new cases 
of low-risk cancer, the quality of life gain was consistently better while the likelihood of 
mpMRI being cost-effective was 86.9%. In conclusion, although mpMRI appears to improve 
quality of life and cost efficiency, more transparent, robust studies clearly focusing on the 
AS setting and taking into account the economic particularities of different healthcare 





The European Association of Urology (EAU) guidelines strongly recommend mpMRI 
prior to a confirmatory biopsy combining both a systematic and targeted approach(63). The 
American Urological Association advocates that mpMRI should be considered during 
surveillance, where high quality MRI is available, with this recommendation based on 
clinical principles or expert opinion(64). The UK National Institute for Clinical Excellence 
(NICE) released a guideline for the diagnosis and management of prostate cancer in 
January 2015(12). This advocates early mpMRI assessment of AS candidates at enrolment 
and with any clinical or PSA change (with or without guided biopsy), although it is less 
prescriptive in terms of histological or biochemical selection criteria and the actual imaging 
protocol that should be followed during surveillance(65).  
The optimal interval between serial mpMRIs in AS is particularly difficult to define. In an 
imaging-based AS cohort with a median interval of 24 months (range 4–73 months) 
between two consecutive mpMRIs, 69% of patients demonstrated radiological progression 
strongly associated with protocol-based treatment change(42). In addition, PI-RADS scores 
of 4 or 5 at baseline accurately predicted Gleason upgrade on subsequent biopsies. It 
should be noted that, on the whole, studies investigating serial mpMRIs overall suffer from 
a lack of standardization. Different authors use different selection criteria, monitoring 
protocols, outcomes and reporting methods, making evidence synthesis particularly 
cumbersome. Large scale, multinational efforts to create a global consensus on AS and the 
various selection and monitoring criteria (including imaging) could mitigate this 
limitation(66). At the moment, a reasonable imaging strategy in AS based on available 
evidence of mpMRI phenotypes and the known natural history of prostate cancer could be 
mpMRI at enrolment, 1 year and then every two years. At our institution (University College 
London Hospitals NHS Trust), mpMRI is performed for all AS patients at baseline and at 1 
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year as advocated by NICE. Beyond the first year, mpMRI is repeated at 12-24 months for 






MpMRI shows great promise in the selection and monitoring of men in AS. It optimizes 
biopsy procedures, as it reduces the number of cores needed to detect clinically significant 
cancer and it minimizes the detection of insignificant disease. In addition, its high NPV for 
the presence of clinically significant tumours (reaching 98% in some studies) means that a 
negative scan could be used to confirm eligibility for AS. MpMRI is highly specific for 
detecting upgrading on confirmatory biopsy (up to 80%) and mpMRI-based parameters 
improve the ability to predict reclassification and upstaging, with an NPV for reclassification 
often exceeding 90%. However, its sensitivity is somewhat lower in the region of 70%. 
Finally, mpMRI could facilitate the monitoring of low-risk lesions in AS patients and reduce 
the need for additional biopsies during surveillance. Adequate training, standardization in 
imaging protocols and reporting and awareness of the modality’s limitations are important to 
accurately stratify risk in the AS setting. 
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Table 1: Recent important studies on the value of mpMRI for confirming AS suitability in men with a 
subsequent biopsy or radical prostatectomy. PRIAS AS criteria: T1c or T2, Gleason ≤6, ≤2 positive cores, 
PSA≤10, PSAD≤0.2. Epstein AS criteria: T1c, PSA ≤10, Gleason ≤6, PSAD ≤ 0.15, ≤ 2 positive cores and 
core involvement ≤50%. NCCN AS criteria (low-risk): Gleason ≤3+3/PGG 1, Stage ≤T2a, PSA ≤10. (TB: 
targeted biopsy, FB: fusion biopsy, CB: confirmatory biopsy, GS: Gleason score, ECE: extracapsular 
extension, NCCN: National Comprehensive Cancer Network).  
 
Table 2: Recent important studies on AS patients undergoing mpMRI and repeat biopsy. Low NIH AS criteria: 
Stage ≤T2a PSA ≤20, Gleason ≤3+3; expanded NIH criteria: stage ≤T2a, PSA ≤20, Gleason ≤3+4, positive 
cores ≤33%. (TB: targeted biopsy, FB: fusion biopsy, SB: systematic biopsy, SN: sensitivity, SP: specificity, 
PPV: positive predictive value, NPV: negative predictive value, PSAD: PSA density).  
 
Table 3: Take-away summative points for mpMRI in active surveillance. 
 
Figure 1: mpMRI sensitivity and specificity for confirming AS suitability in men with a subsequent biopsy or 
radical prostatectomy (representative studies with data directly available for analysis). The first four studies 
use biopsy as a reference standard, whereas the last two use RP. Estimates presented with 95% confidence 
intervals (in brackets). 
 
Figure 2: Prostate MRI for AS candidate selection and monitoring. Left panel: Man on active surveillance for 
a Gleason 3 + 4, 2 mm prostate cancer on the right side. MRIs at different time points show a right peripheral 
zone lesion posteriorly, also characterised by low signal intensity on T2WI (A, D, G, J), restricted diffusion (B, 
E, H, K) and focal enhancement (C, F, I, L). The lesion did not show significantly progress and this man is still 
on AS. Right panel: Man on AS for Gleason 3+4, 8 mm cancer. The mpMRI scan at baseline (2014) shows a 
right peripheral zone lesion between the base and midgland, abutting the prostatic capsule and characterised 
by low signal intensity on T2WI (A, D), restricted diffusion (B, E) and focal enhancement (C, F). In the follow-
up scan (2015), T2W and DCE images suggested progression (increased lesion size and capsular 
enhancement that may represent early T3a disease). This man underwent radical prostatectomy in 2016, 
confirming Gleason 3+4 cancer.  
 
